echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Can the use of allopurinol after stroke reduce the progression of white matter hyperintensity?

    Can the use of allopurinol after stroke reduce the progression of white matter hyperintensity?

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In a randomized trial, the use of allopurinol did not reduce the progression of white matter hyperintensity (WMH) in patients with ischemic stroke or transient ischemic attack (TIA)
    .

    The study showed that the difference in the Rotterdam Progression Score (RPS) between patients who received the xanthine oxidase inhibitor allopurinol and those who received a placebo was 0.
    17, which was not statistically significant
    .

    Yimaitong compiles and organizes, please do not reprint without authorization
    .

    Research Introduction Previous studies have shown that elevated serum uric acid levels are associated with the risk of adverse cardiovascular outcomes (including stroke)
    .

    Xanthine oxidase inhibitors can lower blood uric acid levels and therefore may affect the risk of stroke
    .

    A meta-analysis of a small study showed that allopurinol can lower blood pressure to a certain extent, and may reduce the risk of cardiovascular events in patients with confirmed cardiovascular disease
    .

     Based on the above findings, the researchers conducted a study on whether allopurinol can reduce WMH progression (a marker of stroke risk) and blood pressure after ischemic stroke or TIA
    .

    Researchers recruited patients 50 years of age or older at 22 locations in the UK
    .

     After a four-week run-in period, the researchers randomly assigned the participants to receive 300 mg of allopurinol or placebo twice a day for 104 weeks
    .

    All participants received brain MRI at baseline and 104 weeks, and ambulatory blood pressure monitoring was performed at baseline, 4 weeks, and 104 weeks
    .

     The researchers chose to use the WMH progress measured by RPS as the main result of the study
    .

    Secondary results include the average daytime systolic blood pressure at Week 4 and Week 104
    .

     Main findings: ➤Overall, 189 participants in the placebo group and 183 participants in the allopurinol group underwent MRI examinations at the 104th week
    .

    The RPS of the allopurinol group was 1.
    33 and that of the placebo group was 1.
    51
    .

    The difference between the groups was -0.
    17, which was not statistically significant
    .

     ➤At the 4th week, the daytime systolic blood pressure change in the allopurinol group was -2.
    3mmHg, the placebo group was 0.
    8mmHg, and the difference between the groups was -3.
    33mmHg (P=0.
    0034)
    .

    In the 104th week, there was a significant loss of follow-up
    .

    At that time, the inter-group difference in daytime systolic blood pressure was -2.
    95 mmHg (P=0.
    058)
    .

     Expert comment Louis R.
    Caplan, MD, professor of neurology at Harvard Medical School in Boston, Massachusetts, said that this study “re-causes people's attention to uric acid, but there are many paradoxes about uric acid
    .

    ” Epidemiological studies show that uric acid levels are high.
    Of people are at increased risk of stroke
    .

    But other data suggests that uric acid may have a positive effect
    .

    A 2016 study showed that uric acid treatment can prevent early ischemic exacerbations in acute stroke patients receiving thrombolytic therapy
    .

    There is a lack of correlation between WMH and neurological deficits.
    WMH is not an infarction.
    It is difficult to know what the changes on MRI really mean
    .

     Study author Jesse Dawson, MD, professor of stroke medicine at the University of Glasgow, UK, said: “We were surprised that we did not see a difference in RPS between the allopurinol group and the placebo group
    .

    However, we recognize that WMH may have many other causes, not just It is the flexibility of the cerebrovascular
    .
    The
    lack of effect is consistent with the very complex pathophysiology of WMH that we know to exist
    .

    "Yimaitong compiled from: No Reduction in WMH Progression With Allopurinol After Stroke-Medscape-Nov 15, 2021.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.